DETAILED ACTION
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
The response filed August 28, 2026, has been received and entered.
Claims 3, 4, 18-20, 23-25, and 27-36 are canceled.
Claims 1, 2, 5-17, 21, 22, 26, 37, and 38 are pending.
Election/Restrictions
Applicant’s election without traverse of Group I, claims 1, 2, 5-16, and 22, in the reply filed on August 28, 2026, is acknowledged.
Claims 17, 21, 26, 37, and 38 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected inventions, there being no allowable generic or linking claim.
Claims 1, 2, 5-16, and 22 are examined on the merits.
Drawings
The drawings are objected to because they are not completely legible. In particular, the following are not completely legible: the structure in Figure 1A, the text of Figure 2A is not, the lines and text of Figure 3B, the text of Figures 4D and 4E, the lines and text of Figures 5A-5F, the lines and text of Figures 6A-6C, the text of Figure 10B.
Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance.
Claim Objections
Claims 1, 2, 5-16, and 22 are objected to because of the following informalities:
Claim 1 is objected to because the word “a” should be inserted before the recitation “gene” in line 1. Since claim 1 is objected to, then the claims that incorporate claim 1, claims 2, 5-16, and 22, are objected to.
Claims 1, 2, 5-13, and 16 are objected to because every recitation of “Listeria” should be italicized. Since claim 1, 13, and 16 are objected to, then the claims that incorporate them, which include claims 14, 15, and 22, are objected to.
Appropriate correction is required.
Specification
The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code; references to websites should be limited to the top-level domain name without any prefix such as http:// or other browser-executable code. See MPEP § 608.01. In particular, paragraph [0049] includes browser-executable code.
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 1, 2, 5-16, and 22 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention.
The specification fails to provide adequate written description for the broad genus of a variant Listeria bacterium comprising a mutation in gene required for flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD) biosynthesis, wherein the variant Listeria bacterium does not grow extracellularly in a mammal.
MPEP 2163(II)(A)(3)(a)(ii) recites, “The written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice…, reduction to drawings…, or by disclosure of relevant, identifying characteristics, sufficient to show the inventor was in possession of the claimed genus.”
Regarding representative number of species, MPEP 2163(II)(A)(3)(a)(ii) states, “A ‘representative number of species’ means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus.”
Regarding the identifying characteristics, MPEP 2163(II)(A)(3)(a) states, “An applicant may also show that an invention is complete by disclosure of sufficiently detailed, relevant identifying characteristics which provide evidence that inventor was in possession of the claimed invention, i.e., complete or partial structure, other physical and/or chemical properties, functional characteristics when coupled with a known or disclosed correlation between function and structure, or some combination of such characteristics.” Further still, MPEP 2163(II)(A)(3)(a)(ii) states, “For inventions in an unpredictable art, adequate written description of a genus which embraces widely variant species cannot be achieved by disclosing only one species within the genus.”
In the instant case, Applicant has not described the genus of the claimed variant Listeria bacterium such that the specification might reasonably convey to the skilled artisan that Applicant had possession of the full scope of the claimed invention at the time the application was filed. Because the claims encompass a genus of variant Listeria bacterium, an adequate written description of the claimed invention must include sufficient description of at least a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics sufficient to show that Applicant was in possession of the claimed genus.
Mutations in a gene are well known in the art to include deletions, insertions, and substitutions of at least one nucleic acid of the gene. The specification does not limit the definition of a gene required for FMN and FAD biosynthesis. Therefore, the claimed limitation of a mutation in gene required for FMN and FAD biosynthesis encompasses numerous mutations. Therefore, the genus is highly variant in the claims because a significant number of structural differences between genus members is permitted.
The claims also require that the variant Listeria bacterium does not grow extracellularly in a mammal. When describing the characteristic of not being capable of growing extracellularly in a mammal, the specification indicates that the variant Listeria is a conditionally obligate intracellular bacterium in vivo (paragraph [0029]). The specification discloses in Example 1 experiments testing mutants of Listeria monocytogenes, specifically a mutant comprising a deletion of the ribC gene (ΔribC), a mutant comprising a deletion of the ribF gene (ΔribF) and a mutant comprising deletions of both the ribC and ribF genes (ΔribCΔribF) (particularly paragraphs [0130], [0138], [0149], and [0150]). The ΔribCΔribF mutant was unable to colonize the gallbladder, whereas the ΔribC and ΔribF strains grew extracellularly in the gallbladder (paragraph [0149]; Figure 6A). Likewise, the ΔribCΔribF mutant did not grow extracellularly in blood (paragraph [0150]; Figure 6B), while Figure 6B shows that the ΔribC and ΔribF mutants grew extracellularly in blood. The specification states, “Collectively, these observations suggest that the ΔribCΔribF strain cannot grow extracellularly in the gallbladder, blood, or the GI tract, and that this mutant is restricted to intracellular growth in vivo” (paragraph [0150]). Therefore, the specification describes only a single species that possesses the claimed characteristic of not growing extracellularly in a mammal: a variant Listeria monocytogenes bacterium comprising a deletion of all of the ribC gene and the ribF gene.
The ΔribC and ΔribF mutants of Example 1 are two species which fall within the claimed genus of a variant Listeria bacterium comprising a mutation in gene require for FMN and FAD biosynthesis. Despite falling within that claimed genus, Example 1 demonstrates that they fail to possess the claimed characteristic of not growing extracellularly in a mammal. Given the contrasting property with the ΔribCΔribF strain, the specification fails to the couple a structure with the functional characteristic of not growing extracellularly in a mammal.
Therefore, one of skill in the art would reasonably conclude that the disclosure fails to provide a representative number of species to describe the genus. As such, the Applicant was not in possession of the claimed genus. The claimed subject matter is not fully supported by an adequate written description because a representative number of species has not been described. In sum, while there is written description for a variant Listeria monocytogenes bacterium comprising a deletion of all of the ribC gene and the ribF gene, wherein the variant L. monocytogenes bacterium does not grow extracellularly in a mammal, adequate written description is lacking to demonstrate possession of the full scope of a variant Listeria bacteria as recited in the claims.
Relevant Prior Art
The prior art made of record and not relied upon is considered pertinent to applicant's disclosure:
Fuller (US 5,925,354) discloses a live vaccine against bacterial pathogens comprising a recombinant riboflavin-requiring mutant having a mutation that inactivates riboflavin biosynthesis therein (column 5, lines 9-12). A mutation that inactivates riboflavin biosynthesis is directed to a mutation in a gene required for flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD) biosynthesis because riboflavin is known to be converted first into FMN and then into FAD (paragraph [0005] of the instant specification). Also, Listeria bacteria such as Listeria monocytogenes are well known in the art as bacterial pathogens. Therefore, it would have been obvious to the skilled artisan to apply the teaching of a live vaccine of Fuller to a Listeria bacterium, thereby rendering obvious a variant Listeria bacterium comprising a mutation in a gene required for FMN and FAD biosynthesis.
However, Fuller differs from the claimed invention in that Fuller does not expressly disclose or render obvious such a variant Listeria bacterium that does not grow extracellularly in a mammal. It would not have been obvious that a variant Listeria bacterium having a mutation that inactivates riboflavin biosynthesis possesses the claimed property of not growing extracellularly in a mammal. As indicated in the instant specification, wild-type L. monocytogenes can grow extracellularly in the gallbladder, blood, and the GI tract of mice (paragraph [00149]). Of the three mutants of L. monocytogenes tested in Example 1 of the instant specification which comprise a mutation in a gene required for FMN and FAD biosynthesis, the results suggest that only the ΔribCΔribF mutant does not grow extracellularly in a mammal (paragraphs [0149]-[0150]).
Falb (WO 2017/023818) discloses genetically engineered bacteria that are naturally pathogenic bacteria that are modified or mutated to reduce or eliminate pathogenicity (paragraph [0135] on page 46). Examples of the bacteria include Listeria and Listeria monocytogenes (paragraph [0135] on page 46). Also, in some embodiments, the genetically engineered bacteria comprise a deletion or mutation in two or more genes required for cell survival and/or growth (paragraph [0354] on page 127). Examples of essential genes include ribF and ribC (paragraph [0355]). The ribF and ribC genes are recited in instant claim 2 as genes required for FMN and FAD synthesis. These different teachings in Falb suggest a combination that renders obvious a genetically engineered Listeria bacterium comprising a deletion or mutation in two or more genes required for cell survival and/or growth, wherein the genes can be selected from a group that includes ribF and ribC, thereby rendering obvious a variant Listeria bacterium comprising a mutation in a gene required for FMN and FAD biosynthesis.
However, Falb differs from the claimed invention in that Falb does not expressly disclose or render obvious such a variant Listeria bacterium that does not grow extracellularly in a mammal. There would not have been a reasonable expectation that a genetically engineered L. monocytogenes comprising deletions of all of the ribF and ribC genes has the property of not growing extracellularly in a mammal (an unexpected result in Example 1 of the instant specification). As indicated in the instant specification, wild-type L. monocytogenes can grow extracellularly in the gallbladder, blood, and the GI tract of mice (paragraph [00149]). Of the three mutants of L. monocytogenes tested in Example 1 of the instant specification which comprise a mutation in a gene required for FMN and FAD biosynthesis, the results suggest that only the ΔribCΔribF mutant does not grow extracellularly in a mammal (paragraphs [0149]-[0150]).
Conclusion
No claims are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUSAN EMILY FERNANDEZ whose telephone number is (571)272-3444. The examiner can normally be reached 10:30am - 7pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melenie Gordon can be reached at 571-272-8037. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
Sef
/SUSAN E. FERNANDEZ/Examiner, Art Unit 1651